AMRN Amarin Corp

    RNS Number : 2972V
  Amarin Corporation Plc
  27 May 2008
   



    SCHEDULE 5 DISCLOSURES PURSUANT TO AIM/IEX RULE 17

    New Amarin Directors Pursuant to May 2008 Private Placement

    James Healy, M.D., Ph.D., aged 43, joined Sofinnova Ventures as a General Partner in 2000.  Dr. Healy, was a founding investor and board
member of Cellective (acquired by MedImmune), CoTherix (acquired by Actelion), Novacea, and Intermune. He also serves as a director of
Anthera Pharmaceuticals, Hyperion Therapeutics, InteKrin Therapeutics, KaloBios, Movetis, Nextwave, Phenomix, Preglem, Prestwick
Pharmaceuticals, Sorbent and Cebix. He no longer serves on the board of directors of Cellective and CoTherix.

    In the pharmaceutical industry Dr. Healy held positions at Bayer Pharmaceuticals (Miles) and ISTA Pharmaceuticals prior to its initial
public offering. He began his private equity career at Sanderling. Dr. Healy earned B.A.s in Molecular Biology and Scandinavian Studies from
the University of California at Berkeley, where he graduated with Distinction in General Scholarship, Honors, and received a Departmental
Citation. He received his M.D. from Stanford University*s School of Medicine through the Medical Scientist Training Program, and earned his
Ph.D. in Immunology from Stanford University, where he was a Beckman Scholar and received a bursary award from the Novartis Foundation. Dr.
Healy teaches a course on entrepreneurship at Stanford University, and is an active member of the BIO-NVCA Working Group. 

    
Sofinnova Ventures currently hold 3,586,957 Ordinary Shares/ADSs in Amarin, with no warrants or share options.  The Sofinnova Ventures
holding in Amarin was acquired in Amarin's recently announced private placement of equity.


    Carl Lee Gordon, Ph. D., CFA, aged 43, is a founding General Partner and Co-Head of Private Equity of OrbiMed Advisors LLC. Dr. Gordon
is active in both private equity and small-capitalization public equity investments. He was a senior biotechnology analyst at Mehta and
Isaly from 1995 to 1997. He was a Fellow at The Rockefeller University from 1993 to 1995. Dr. Gordon received a Ph.D. in Molecular Biology
from the Massachusetts Institute of Technology. His doctoral work involved studies of protein folding and assembly. He received a Bachelors
degree from Harvard College. 

    OrbiMed Advisors LLC currently holds 3,260,870 Ordinary Shares/ADSs in Amarin, with no warrants or share options.  The OrbiMed Advisors
LLC holding in Amarin was acquired in Amarin's recently announced private placement of equity.

    Dr. Eric Aguiar, aged 46, is a Partner at Thomas, McNerney & Partners. He also serves as a director of Oriel Therapeutics. He has 16
years of experience in the biopharmaceutical industry. From 2001 to 2007 he was a Managing Director at HealthCare Ventures LLC. Prior to
joining HealthCare Ventures, he was CEO of Genovo, Inc.  Dr. Aguiar was an executive at TheraTech, a drug delivery company that was sold to
Watson Pharmaceuticals in 1997. He was a Managing Director and Vice President of Philadelphia Ventures in the mid-1990's.  He has previously
served as a director of CardioKine, SkinMedica, Vaxinnate, Metaphore Pharmaceuticals, 3-D Pharmaceuticals, and ThromboSys. He graduated from
Harvard Medical School and Cornell University with honors.

    Thomas, McNerney & Partners currently holds 2,173,913 Ordinary Shares/ADSs in Amarin, with no warrants or share options. The Thomas,
McNerney & Partners holding in Amarin was acquired in Amarin's recently announced private placement of equity.

    Dr. Srinivas Akkaraju, aged 40, is a founding Managing Director of Panorama Capital and focuses primarily on life sciences investments.
Previously, he was with J.P. Morgan Partners, serving as a Principal, starting in April 2001 and becoming a Partner in January 2005. From
1998 to 2001, Dr. Akkaraju was in Business and Corporate Development at Genentech, Inc., most recently as Senior Manager responsible for
worldwide partnering activities, in-licensing of therapeutics, and out-licensing of development projects. In addition to his business
development role, Dr. Akkaraju also served as a Project Team Leader for one of Genentech's clinical development products. During this time,
he also was a founding member of BioStreet, an online marketplace for biotech opportunities. Dr. Akkaraju holds B.A. degrees in both
Biochemistry and Computer Science from Rice University and an M.D. and Ph.D. in Immunology from Stanford University School of Medicine. Dr.
Akkaraju currently serves as a director of Presidio Pharmaceuticals, Itero Biopharmaceuticals, Barrier Therapeutics, Inc., Phenomix Corporation, Piramed Limited, Seattle Genetics, Inc., and Pharmos,
Inc.  He has previously served as a director of Microscience, Eyetech Pharmaceuticals and Vela Pharmaceuticals.

    Panorama Capital currently holds 1,847,826 Ordinary Shares/ADSs in Amarin, with no warrants or share options. The Panorama Capital
holding in Amarin was acquired in Amarin's recently announced private placement of equity.

    Save as disclosed above, there are no details specified by Schedule 2(g)(i) to (viii) of the AIM Rules and the IEX Rules to be disclosed
in relation to the above mentioned directors.

    Current Amarin Directors who Participated in May 2008 Private Placement

    Sunninghill Limited, which is an entity controlled by Dr. John Climax, a non-executive director of the Company, acquired 521,739
Ordinary Shares/ADSs at $2.30 per share in the Amarin's recently announced private placement of equity. Sunninghill Limited's resultant
holding 1,465,755 Ordinary Shares/ADSs represents 5.42% of Amarin's Ordinary Share capital.

    Significant Amarin Shareholders who Participated in May 2008 Private Placement

    Dr. Simon Kukes, a former non executive director of Amarin, acquired 326,087 Ordinary Shares/ADSs at $2.30 per share in the Amarin's
recently announced private placement of equity. Dr. Kukes now holds 1,277,695 Ordinary Shares/ADSs which represents 4.72% of Amarin's
Ordinary Share capital.

    About Amarin
    Amarin is a biopharmaceutical company focused on improving the lives of patients suffering from cardiovascular and central nervous
system (CNS) diseases. Amarin's cardiovascular programs capitalize on the known therapeutic benefits of essential fatty acids in
cardiovascular disease. Amarin's CNS development pipeline includes programs in myasthenia gravis, Huntington's disease, Parkinson's disease,
epilepsy and memory. Amarin also has two proprietary technology platforms: a lipid-based technology platform for the targeted transport of
molecules through the liver and/or to the brain, and a unique mRNA technology based on cholinergic neuromodulation. Amarin has its primary
stock market listing in the U.S. on the NASDAQ Capital Market ("AMRN").


    Contacts: 
    Amarin +353 (0)1 669 9020 
    Thomas Lynch, Chairman and Chief Executive Officer
    Alan Cooke, President and Chief Operating Officer
    Darren Cunningham, EVP Strategic Development and Investor Relations
    investor.relations@amarincorp.com 

    Investors: 
    Lippert/Heilshorn & Associates, Inc. 
    Anne Marie Fields +1 212 838 3777
    Bruce Voss +1 310 691 7100 

    Media: 
    Powerscourt +44 (0) 207 250 1446 
    Rory Godson 
    Paul Durman 



This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
RDNPUUGAAUPRGUM

Amarin (LSE:AMRN)
Historical Stock Chart
From Apr 2024 to May 2024

Amarin (LSE:AMRN)
Historical Stock Chart
From May 2023 to May 2024